Allogeneic hematopoietic stem-cell transplantation for myelofibrosis

Area of Science:

• Hematology
• Oncology
• Stem Cell Transplantation

Background:

• Myelofibrosis is a Philadelphia chromosome-negative myeloproliferative neoplasm with varied clinical outcomes.
• While treatments like JAK inhibitors improve survival, allogeneic hematopoietic stem-cell transplantation (AHSCT) is the only potentially curative option.
• Deciding on AHSCT timing and patient eligibility is critical due to associated risks.

Purpose of the Study:

• To review recent advancements in allogeneic hematopoietic stem-cell transplantation for myelofibrosis.
• To discuss key factors influencing AHSCT outcomes, including patient selection, pre-transplant conditions, and donor factors.
• To address the management of relapse, a significant cause of treatment failure post-AHSCT.

Main Methods:

• Review of current literature and recent data on AHSCT for myelofibrosis.
• Analysis of factors impacting transplant success: patient selection, splenectomy, conditioning regimens, donor type, and molecular mutations.
• Examination of strategies for minimal residual disease monitoring and relapse management.
• Inclusion of emerging data on pre-transplant ruxolitinib therapy.

Main Results:

• Allogeneic hematopoietic stem-cell transplantation is the only potentially curative therapy for myelofibrosis.
• Patient selection, splenectomy, conditioning regimen, donor type, and molecular mutations significantly affect AHSCT outcomes.
• Relapse remains a major challenge, necessitating effective monitoring and management strategies.
• Pre-transplant ruxolitinib shows promising results, warranting further investigation.

Conclusions:

• Optimizing patient selection and management strategies are crucial for successful allogeneic hematopoietic stem-cell transplantation in myelofibrosis.
• Effective monitoring and treatment of minimal residual disease and relapse are essential for improving long-term outcomes.
• Further research is needed to fully integrate novel therapies like ruxolitinib into the AHSCT paradigm for myelofibrosis.